PAIN+ CPN

Kocak AO Intradermal mesotherapy versus systemic therapy in the treatment of musculoskeletal pain: A prospective randomized study. Am J Emerg Med. 2019 Feb 28. pii: S0735-6757(19)30146-9. doi: 10.1016/j.ajem.2019.02.042. (Original study)
Abstract

INTRODUCTION: Acute musculoskeletal injuries are one of the most common painful presentation when admission to the emergency department. The aim of the study is to compare the tenoxicam mesotherapy with intravenous dexketoprofen in pain control in patients with acute musculoskeletal injury.

METHODS: This parallel randomized controlled trial was conducted with the patients admitted to the emergency department with musculoskeletal injury. Intravenous dexketoprofen was administered to the control group, and mesotherapy treatment was performed to the other group. Differences between 10th, 30th, 60th and 120th minutes VAS scores and on the admission VAS score, clinically meaningful change in pain intensity, and adverse effect of the procedures were compared among groups.

THE RESULTS: The differences in VAS scores and the presence of clinically meaningful change in pain intensity were statistically significantly higher in mesotherapy group than the systemic therapy group in all time periods. During one-week follow-up period, there was no reported adverse effect neither in mesotherapy group nor in the systemic therapy group.

CONCLUSIONS: The mesotherapy treatment may be superior than the systemic therapy for pain relief in musculoskeletal injury in short term follow-up in emergency department settings.

Ratings
Discipline Area Score
Physician 5 / 7
Show me more articles about:
  Acute Pain
Comments from MORE raters

Physician rater

Intradermal mesotherapy is a treatment modality that requires advanced training, and comparing this to intravenous NSAID administration may be difficult (no blinding possible). This is a promising article overall, however.
Comments from PAIN+ CPN subscribers

No subscriber has commented on this article yet.